Resolvin D1 Inhibits IL-6-Induced Epithelial-Mesenchymal Transition of Colorectal Cancer Cells by Targeting IL-6/STAT3 Signaling

  • Cell Biochem Biophys. 2024 May 13. doi: 10.1007/s12013-024-01299-5.
Heng Du  #  1 ,  Lijuan You  #  2 ,  Anding Wu  1 ,  Fei Wang  1 ,  Jie Yu  1 ,  Chaowu Chen  3
Affiliations
  • 1. Department of Gestrointestinal Surgery, Huanggang Central Hospital Affiliated to Yangtze University, Changsha, 438000, China.
  • 2. Department of Anesthesiology, Huanggang Central Hospital Affiliated to Yangtze University, Changsha, 438000, China.
  • 3. Department of Gestrointestinal Surgery, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, 438000, China. [email protected].
  • # Contributed equally.
PMID: 38740668 DOI: 10.1007/s12013-024-01299-5
Abstract

Colorectal Cancer (CRC) has emerged as a prevalent malignancy worldwide, exhibiting the high morbidity and mortality rates. Resolvin D1 (RvD1) can exert anti-inflammation and anti-cancer effects on various diseases. This study is aimed to explore the role of RvD1 in CRC cells. HCT15 and SW480 cells were stimulated with IL-6 in our study. A series of assays such as CCK-8, colony formation, wound healing, Transwell, Western blotting, and immunofluorescence staining were designed and conducted to figure out the role of RvD1 in CRC cells. RvD1 suppressed IL-6-induced SW480 and HCT15 cell proliferation. In addition, RvD1 inhibited IL-6-induced SW480 and HCT15 cell migration, invasion, and EMT process. In mechanism, RvD1 inhibited the activation of IL-6/STAT3 signaling in SW480 and HCT15 cells. Angoline strengthened the inhibitive effect of RvD1 on cell malignancy. RvD1 inhibited cell growth, migration, invasion and EMT process by inactivating IL-6/STAT3 signaling in CRC.

Keywords
CRC; EMT; IL-6/STAT3; RvD1.
Products
Inhibitors & Agonists
Other Products